α-Synuclein strain homogeneity in multiple system atrophy clinical subtypes
Lau, H. H. C.; Silver, N. R. G.; Mehra, S.; So, R. W. L.; Li, L. y.; Mao, A.; Stuart, E.; Schmitt-Ulms, C.; Hyman, B. T.; Ingelsson, M.; Watts, J. C.
Show abstract
Conformationally distinct strains of -synuclein aggregates are believed to contribute to the clinical and pathological diversity observed among synucleinopathies such as multiple system atrophy (MSA) and Parkinsons disease. Cases of MSA can be classified into two distinct clinical subtypes: the cerebellar variant, MSA-C, and the parkinsonian variant, MSA-P. To assess whether distinct -synuclein strains may be present in individuals with MSA-C versus MSA-P, we characterized the conformational and seeding properties of -synuclein aggregates in various brain regions from MSA-C and MSA-P patients and performed propagation studies in M83 transgenic mice. Biochemical fingerprinting of -synuclein aggregates using limited proteolysis and a conformational stability assay failed to reveal differences between MSA-C and MSA-P either before or after propagation in mice. Similarly, using brain extracts from either MSA patients or MSA-inoculated mice, MSA-C and MSA-P -synuclein aggregates exhibited indistinguishable seeding attributes in a seed amplification assay. Finally, no differences were observed in either the kinetics of disease progression or the extent of cerebral -synuclein deposition in M83 mice inoculated with either MSA-C or MSA-P, regardless of the brain region from which the injected -synuclein aggregates were derived. These results suggest that MSA clinical subtypes are unlikely to arise due to distinct -synuclein strains. Instead, our findings support a model in which the same -synuclein strain initially forms in different brain regions, leading to differences in disease manifestation.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Neuronal titration of Snca via enhancer disruption mitigates disease onset in a Parkinson's disease mouse model 95%
- A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease 94%
- Epsin2, a novel target for multiple system atrophy therapy via α-synuclein/FABP7 propagation 93%
Similar papers in this journal
- A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies 95%
- MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity 95%
- Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain 95%
Similar papers in this journal
- Essential tremor with tau pathology features seeds indistinguishable in conformation from Alzheimer's disease and primary age-related tauopathy 95%
- Nuclear depletion of RNA binding protein ELAVL3 (HuC) in sporadic and familial amyotrophic lateral sclerosis 95%
- Dysregulated coordination of MAPT exon 2 and exon 10 splicing underlies different tau pathologies in PSP and AD 94%
Similar papers in this journal
- VPS35 and α-Synuclein Fail to Interact to Modulate Neurodegeneration in Rodent Models of Parkinson's Disease 94%
- β-Amyloid Induces Microglial Expression of GPC4 and APOE Leading to Increased Neuronal Tau Pathology and Toxicity 93%
- Alpha-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinsons disease 93%
Similar papers in this journal
- Divergent and Convergent TMEM106B Pathology in Murine Models of Neurodegeneration and Human Disease 94%
- CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington's disease 94%
- α-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.